Ceftazidime therapy for serious infections.
Thirty-two episodes of severe infection in 23 patients were treated with parenteral ceftazidime: 96% of the infections were cured or improved. Of 15 chest infections in cystic fibrosis patients, 14 responded satisfactorily to treatment, including 9 cases where Pseudomonas aeruginosa and 7 cases where Staphylococcus aureus was a pathogen. All seven cases of peritonitis in peritoneal dialysis patients were cured or improved. Other infections that responded to treatment were urinary tract infections (3), septicaemias (2), wound infections (2), acute bronchitis (2) and cholangitis (1). Ceftazidime was shown to produce good blood and peritoneal dialysis fluid levels and to penetrate into sputum. Adverse effects were few and not serious.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002442:Ceftazidime